When pharmaceutical companies develop medications for serious diseases like prostate cancer, few anticipate how those treatments might transform care for entirely different patient populations. Yet,
Altimmune has released updated 48-week results from its phase 2 trial of pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH),
CRISPR Therapeutics has announced encouraging early results for zugocaptagene geleucel (zugo-cel), its investigational allogeneic CAR T therapy targeting CD19, in both autoimmune diseases and hematologic
As reported on PharmaBiz, Amneal Pharmaceuticals, in collaboration with mAbxience, has received U.S. Food and Drug Administration (FDA) approval for two denosumab biosimilars: Boncresa (referencing
As reported on Science Daily, a groundbreaking study suggests that customizing breast cancer screening based on individual risk factors may outperform the traditional one-size-fits-all approach
Coya Therapeutics has achieved an important regulatory milestone with U.S. FDA acceptance of an Investigational New Drug (IND) application for COYA 302, marking the advancement
In a recent statement, the U.S. Food and Drug Administration (FDA) has authorized regular approval to rucaparib (Rubraca) for adults with metastatic castration-resistant prostate cancer
A new oral medication has demonstrated remarkable effectiveness in treating hereditary angioedema (HAE) attacks, offering patients significantly faster symptom relief compared to existing options. According
Incyte has announced encouraging top-line findings from its pivotal Phase III frontMIND trial, evaluating tafasitamab (marketed as Monjuvi/Minjuvi) in combination with lenalidomide and the standard
Researchers at Oregon Health & Science University have made a significant breakthrough in the fight against acute myeloid leukaemia (AML), discovering that combining a standard
I’ve always known that I wanted to help people. Growing up as the son of a veterinarian and a high school teacher who later became
Iowa University researchers at its Children’s Hospital led the effort that found a new target. According to the Iowa Carver College of Medicine, to date,
Editor’s Note: The following study results were first published in Nephrology Dialysis Transplantation (December 16, 2025) and later shared in the Oxford Academic. The original
Otsuka has claimed a significant victory in the increasingly competitive immunoglobulin A nephropathy (IgAN) field with FDA accelerated approval of Voyxact, the first-in-class anti-APRIL biologic
As reported on FiercePharma, Johnson & Johnson has secured a significant milestone in prostate cancer treatment with the FDA’s approval of Akeega for patients with
A groundbreaking study from Massachusetts General Hospital reveals that artificial intelligence is catching breast cancers that skilled radiologists initially overlook. As reported by Business Wire,
There’s a lot to consider when you’re facing tumor removal surgery. Think about mandible or jaw surgery, for example. Your face is part of every
As reported on PharmaBiz, GENESIS Pharma has announced an exclusive agreement with Otsuka Pharmaceutical Europe Ltd. (OPEL) to distribute and commercialize donidalorsen across 14 Central
IgAN affects millions globally, yet many people don't understand what it is. Swipe to learn more about this kidney disease and share your story with us here: bit.ly/4dV7gru #igan #iganephropathy #KidneyHealth
From our friends Neurofibromatosis NetworkMeet Sarah Powlison. She joined the NF Network Advocacy program last year and has proven to be an amazing voice for NF. Read her inspiring thoughts below.
I was diagnosed with Neurofibromatosis Type 1 (NF1) the day I was born. My mom and older sister also have NF1, and a pregnancy scan had revealed a mass on my face. I was born with six tumors, about the size of an orange, growing out of my mouth. This, along with multiple café-au-lait spots (CALs), confirmed the suspicion that I have NF1. I was fortunate to have the tumors removed when I was just a few days old.
Read more Here: www.nfnetwork.org/pages-news/embracing-hope-my-journey-with-neurofibromatosis-and-the-power-of-ad...
#neurofibromatosis #NF #nfadvocates
A Cure In Sight Ocular Melanoma #RareDiseaseDay🏛️ Rare Disease Hill Day | Feb 23–26, 2026 | Washington, DC
A Cure in Sight (ACIS) is heading to Capitol Hill with the EveryLife Foundation for Rare Disease Week. We’ll meet with Members of Congress to advocate for increased rare disease research funding and faster access to treatments.
🎯 Our goal:
Bring a unified, patient-driven message directly to lawmakers — because rare disease patients can’t wait.
🤝 ACIS community events:
💬 Hill Day advocacy prep meeting
🍽️ Community dinner to connect and share stories
📝 Join us in DC or virtually:
forms.gle/N2QhTN6ExsPpcdLk8
💙🖤 Let’s make rare disease a priority on Capitol Hill.
#HillDay #RareDiseaseWeek #ACureInSight #SeeACure
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
